Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
1 - 20 . (canceled)
21 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 5 and a pharmaceutically acceptable carrier or vehicle therefore.
22 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 7 and a pharmaceutically acceptable carrier or vehicle therefore.
23 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 9 and a pharmaceutically acceptable carrier or vehicle therefore.
24 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 11 and a pharmaceutically acceptable carrier or vehicle therefore.
25 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 13 and a pharmaceutically acceptable carrier or vehicle therefore.
26 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 15 and a pharmaceutically acceptable carrier or vehicle therefore.
27 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 17 and a pharmaceutically acceptable carrier or vehicle therefore.
28 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 19 and a pharmaceutically acceptable carrier or vehicle therefore.
29 . An isolated (+) enantiomer of the compound of claim 1 substantially free of its corresponding (−) enantiomer.
30 . An isolated (−) enantiomer of the compound of claim 1 substantially free of its corresponding (+) enantiomer.
31 - 71 . (canceled)